Back to:

Patient adherence and persistence with oral anticancer treatment

Authors

  • Kathryn Ruddy,
  • Erica Mayer,
  • Ann Partridge
  • DOI:10.3322/caac.20004

Citing Literature

  • Number of times cited: 237
  1. 1Salvatore Del Prete, Gregorio Cennamo, Luigi Leo, Liliana Montella, Bruno Vincenzi, Maria Biglietto, Francesca Andreozzi, Antonella Prudente, Patrizia Iodice, Clementina Savastano, Anna Nappi, Vincenzo Montesarchio, Raffaele Addeo, Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study, Future Oncology, 2017, 13, 5, 415CrossRef
  2. 2Laurel Kovacic, Neil de Haan, Mário L de Lemos, Kimberly Schaff, Susan Walisser, Adherence with capecitabine: A population-based analysis based on prescription refill data, Journal of Oncology Pharmacy Practice, 2017, 23, 4, 284CrossRef
  3. 3James J. Lee, Edward Chu, Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102), Clinical Colorectal Cancer, 2017, 16, 2, 85CrossRef
  4. 4Cheryl Lin, Rachel Clark, Pikuei Tu, Hayden B. Bosworth, Leah L. Zullig, Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers, Breast Cancer Research and Treatment, 2017CrossRef
  5. 5Sapna Kaul, Jaqueline C. Avila, Hemalkumar B. Mehta, Ana M. Rodriguez, Yong-Fang Kuo, Anne C. Kirchhoff, Cost-related medication nonadherence among adolescent and young adult cancer survivors, Cancer, 2017, 123, 14, 2726Wiley Online Library
  6. 6Brahmeshwar Mishra, Sundeep Chaurasia, Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles, Therapeutic Delivery, 2017, 8, 1, 29CrossRef
  7. 7Zhiyuan Zheng, Xuesong Han, Gery P. Guy, Amy J. Davidoff, Chunyu Li, Matthew P. Banegas, Donatus U. Ekwueme, K. Robin Yabroff, Ahmedin Jemal, Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States, Cancer, 2017, 123, 8, 1453Wiley Online Library
  8. 8Christopher W Ryan, Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma, Journal of Oncology Pharmacy Practice, 2017, 23, 1, 43CrossRef
  9. 9Evelina Cardoso, Chantal Csajka, Marie P. Schneider, Nicolas Widmer, Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs, Clinical Pharmacokinetics, 2017CrossRef
  10. 10Olivia Meggetto, Elizabeth Maunsell, Rowan Chlebowski, Paul Goss, Dongsheng Tu, Harriet Richardson, Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial, Journal of Clinical Oncology, 2017, 35, 6, 629CrossRef
  11. 11Grant Middendorff, Rachel Elsey, Brian Lounsbery, Roxanne Chadwell, Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents, Journal of Oncology Pharmacy Practice, 2017, 107815521770802CrossRef
  12. 12Chloé Gervès-Pinquié, Fatima Daumas-Yatim, Benoît Lalloué, Anne Girault, Marie Ferrua, Aude Fourcade, François Lemare, Mario Dipalma, Etienne Minvielle, Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial, BMC Health Services Research, 2017, 17, 1CrossRef
  13. 13J. E. H. M. Hoekstra-Weebers, M. H. M. van der Linden, Leerboek oncologie, 2017, 635CrossRef
  14. 14Teresa White, Heidi Larson, Alexandra Minnella, Howard Hochster, Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil
, Clinical Journal of Oncology Nursing, 2017, 21, 2, E30CrossRef
  15. 15Joel Nathan Fishbein, Lauren Ellen Nisotel, James John MacDonald, Nicole Amoyal Pensak, Jamie Michele Jacobs, Clare Flanagan, Kamal Jethwani, Joseph Andrew Greer, Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development, JMIR Research Protocols, 2017, 6, 4, e62CrossRef
  16. 16Madhu Gupta, Vikas Sharma, Nagendra S. Chauhan, Nanostructures for Oral Medicine, 2017, 467CrossRef
  17. 17Joleen M. Hubbard, Axel Grothey, Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor, Drugs, 2017, 77, 10, 1091CrossRef
  18. 18Laura A. Fennimore, Pamela K. Ginex, Oral Agents for Cancer Treatment, Nursing Clinics of North America, 2017, 52, 1, 115CrossRef
  19. 19Jessica A. Zerillo, Kathleen E. Walsh, Patient Safety and Quality in Pediatric Hematology/Oncology and Stem Cell Transplantation, 2017, 239CrossRef
  20. 20Valentina Sini, Andrea Botticelli, Gianluigi Lunardi, Stefania Gori, Paolo Marchetti, Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients, Pharmacogenomics, 2017, 18, 8, 821CrossRef